tbuckley/cabot-search huggingface dataset:
Patterns of trastuzumab use and cost in a single Canadian cancer institute
Authors: K. R. Potvin, T. Younis, M. Sellon, P. Barnes, D. Rayson
Journal: Journal of Clinical Oncology (2005)

6070 Background: Trastuzumab is approved for treatment of HER2/neu over-expressing metastatic breast cancer. There is an absence of data on the costs associated with trastuzumab-based treatment strategies in actual clinical practice. This study was undertaken to identify the strategies currently employed in a single Canadian cancer centre and to explore the costs associated with each strategy. Methods: We performed a retrospective review of all patients treated with trastuzumab at our centre since its approval in Canada. Data was collected using pharmacy records in conjunction with patient charts. Fifty-three patients had complete treatment data and were included in the analysis. Treatment strategies were identified based on timing of trastuzumab initiation. Mean number of cycles (1 cycle = trastuzumab weekly x 3, or Q3 weeks x 1), mean cost per patient and total cost were calculated for each strategy. Results: Four strategies were identified: first-line trastuzumab combined with chemotherapy followed by maintenance trastuzumab (T/C - T); first-line monotherapy (T); second-line or beyond combined with chemotherapy (t/c) and second-line or beyond monotherapy (t). The results are summarized in the table below. The costs reflect trastuzumab only and do not include the cost of additional chemotherapy. Only one patient received first-line monotherapy hence values in the table for “T” represent actual costs. Fifty-eight percent of patients who progressed after first-line therapy continued to receive trastuzumab after progression compared to only 33% progressing after second-line therapy. The total cost of treatment for 53 patients thus far is greater than 1.6 million dollars (Cdn.). Conclusions: Our data highlights the potential costs to be faced by health care systems as novel targeted therapies become available. It further emphasizes the importance of identifying optimal treatment strategies using these agents to ensure appropriate resource allocation. No significant financial relationships to disclose.
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia.
Authors: Ilaria Iacobucci, Daniela Erriquez, Anna Ferrari, Cristina Papayannidis, Claudia Venturi, Stefania Trino, Viviana Guadagnuolo, Annalisa Lonetti, Federica Cattina, Emanuela Ottaviani, Maria Chiara Abbenante, Sarah Parisi, Simona Soverini, Domenico Russo, Fabrizio Pane, Michele Baccarani, Giovanni Perini, Giovanni Martinelli
Journal: Blood (2012)
Targeting FGFR3 in t(4;14) Mutiple Myeloma: Pre-Clinical Studies of PRO-001, a Novel Anti-FGFR3 Neutralizing Antibody.
Authors: Suzanne Trudel, Ellen Wei, Zhi Hua Li, Eran Rom, Ira Chumakov, Yossi Singer, Chris Chen, Donna Reece, Joseph Mikhael, A. Keith Stewart, Avner Yayon
Journal: Blood (2004)
Whole-genome analysis of introgressive hybridization and characterization of the bovine legacy of Mongolian yaks
Authors: Ivica Medugorac, Alexander Graf, Cécile Grohs, Sophie Rothammer, Yondon Zagdsuren, Elena Gladyr, Natalia Zinovieva, Johanna Barbieri, Doris Seichter, Ingolf Russ, André Eggen, Garrett Hellenthal, Gottfried Brem, Helmut Blum, Stefan Krebs, Aurélien Capitan
Journal: Nature Genetics (2017)
Effective Graft-Versus-Leukemia Responses Are Associated with the Presence of Nucleic Acid-Immunoglobulin Complexes That Stimulate TLR8 and TLR9.
Authors: Yun Lin, Terry Means, Edwin P. Alyea, Christine M. Canning, Robert J. Soiffer, Jerome Ritz, Catherine J. Wu
Journal: Blood (2006)
Public attitudes towards psychiatry and psychiatric treatment at the beginning of the 21st century: a systematic review and meta‐analysis of population surveys
Authors: Matthias C. Angermeyer, Sandra van der Auwera, Mauro G. Carta, Georg Schomerus
Journal: World Psychiatry (2017)

Public attitudes towards psychiatry are crucial determinants of help‐seeking for mental illness. It has been argued that psychiatry as a discipline enjoys low esteem among the public, and a “crisis” of psychiatry has been noted. We conducted a systematic review and meta‐analysis of population studies examining public attitudes towards various aspects of psychiatric care. Our search in PubMed, Web of Science, PsychINFO and bibliographies yielded 162 papers based on population surveys conducted since 2000 and published no later than 2015. We found that professional help for mental disorders generally enjoys high esteem. While general practitioners are the preferred source of help for depression, mental health professionals are the most trusted helpers for schizophrenia. If respondents have to rank sources of help, they tend to favor mental health professionals, while open questions yield results more favorable to general practitioners. Psychiatrists and psychologists/psychotherapists are equally recommended for the treatment of schizophrenia, while for depression psychologists/psychotherapists are more recommended, at least in Europe and America. Psychotherapy is consistently preferred over medication. Attitudes towards seeking help from psychiatrists or psychologists/psychotherapists as well as towards medication and psychotherapy have markedly improved over the last twenty‐five years. Biological concepts of mental illness are associated with stronger approval of psychiatric help, particularly medication. Self‐stigma and negative attitudes towards persons with mental illness decrease the likelihood of personally considering psychiatric help. In conclusion, the public readily recommends psychiatric help for the treatment of mental disorders. Psychotherapy is the most popular method of psychiatric treatment. A useful strategy to further improve the public image of psychiatry could be to stress that listening and understanding are at the core of psychiatric care.
The Inhibitor of VEGF-Receptors Tyrosine Kinase PTK-787 Blocks the Invasive Potential of Adult T-Cell Leukemia Cells through the Endothelium.
Authors: Ali Bazarbachi, Roa Harb, Hilda Khoury, Lara Haddad, Youmna Kfoury, Lamia Atweh, Eva Hamadeh, Olivier Hermine, Hugues de The, Marwan E. El-Sabban
Journal: Blood (2004)
RUNX1/CBFβ Dosage Is Critical for MLL Leukemias Development
Authors: Xiaomei Yan, Yoshihiro Hayashi, Xinghui Zhao, Aili Chen, Yue Zhang, Fuhong He, Yunzhu Dong, Yalan Rao, Bo Li, Rajeana Conway, Alba Maiques-Díaz, Nuomin Huang, Shannon E Elf, Johannes Zuber, Zhijian Xiao, William Tse, Daniel G. Tenen, Qianfei Wang, Wei Chen, James C. Mulloy, Stephen D Nimer, Gang Huang
Journal: Blood (2014)
The Expansion of Gastrointestinal-associated αβ T Cell Clones in Peripheral Blood Over Time Is a Disease Feature of Severe Acute Graft-Versus-Host Disease
Authors: Everett H. Meyer, Joanna Liliental, Mareike Florek, Andrea Löhr, Andro Hsu, David Scott Johnson, David B Miklos, James L. Zehnder, Robert S. Negrin
Journal: Blood (2012)
The role of fusion positron emission tomography/computed tomography (PET/CT) scan in patients with resectable pancreatic neoplasms.
Authors: Saqib Razzaque, Noman Ashraf, Jill M. Weber, Jose Mario Pimiento, Mokenge Peter Malafa, Richard D. Kim
Journal: Journal of Clinical Oncology (2012)

322 Background: The role of fusion positron emission tomography/computed tomography scans (PET/CT) in staging of patients with pancreatic neoplasms (PN) is poorly defined. Currently PET/CT is not recommended as part of staging workup in patients with potentially resectable PN. Methods: Using a comprehensive cancer PET registry we identified 107 patients with PN who were potentially resectable based on the initial preoperative staging CT scans and endoscopic ultrasound (EUS), from January 2006 - December 2010. Subsequently all these patients had PET/CT performed prior to surgery. Patients with borderline resectable or locally advanced disease were excluded from the analysis. Statistical analyses were performed included sensitivity, specificity, positive predictive value, and negative predictive value. Statistical analyses were performed with STATA IC (Stata Statistical Software, Release 10.0; Strata Corp., College Station, TX). Results: PET/CT altered management and prevented futile surgery in 6.5 % patients by identifying metastases not detected by other modalities. One patient was found to have metastasis to the supraclavicular lymph node, five had occult hepatic lesions and another had peri-esophageal lymph nodes. All sites were biopsied and metastases confirmed by pathology. The sensitivity and specificity of PET/CT scan in detecting metastatic disease in this patient population was 42.1% and 83.3% respectively. Our study indicated a positive predictive value of PET/CT to be 40% and negative predictive value 84.5%, with a false positive rate of 16.6%. Conclusions: PET/CT was instrumental in preventing futile laprotomy in 6.5 % patients. Larger studies utilizing PET/CT in the initial preoperative staging workup are warranted.
TRAIL as the ATO-Target Gene Uniquely Activated In the Hyperdiploid Subtype of Myeloma with Prognostic Relevance, Resulting In Better Prognosis
Authors: Jumei Shi, Jun Hou, Yi Tao, Xiuqin Meng, Ying Han, Maurizio Zangari, Guido J. Tricot, Fenghuang Zhan
Journal: Blood (2010)
Epidemic Influenza. A Survey.
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Risk-Adapted Induction and Maintenance with Ofatumumab in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
Authors: Inhye Ahn, Mohammed Farooqui, Yuh Shan Lee, Gerald Marti, Susan Soto, Xin Tian, Maryalice Stetler-Stevenson, Constance M. Yuan, Irina Maric, Adrian Wiestner
Journal: Blood (2015)
T(6;9)-DEK/CAN-Positive Leukemia: Role of FLT3-ITD for the Determination of the Leukemic Phenotype
Authors: Maria Heinssmann, Lena Drangmeister, Katharina Schmid, Maren Keller, Hubert Serve, Claudia Oancea, Martin Ruthardt, Gesine Bug
Journal: Blood (2012)
Circulating Invariant Natural Killer T Cell Subsets Are Functionally Preserved in Splenectomized Children with Sickle Cell Disease Compared to Patients with Large Spleen
Authors: Mohamed-Rachid Boulassel, Abeer Al-Zubaidi, Ismail Beshlawi, Zahra Al-Qarni, Nidaa Al-Naamany, Shoaib Al-Zadjali, Sulaiman Al-Hashmi, Hamad Khan, Mohammed Al Huneini, Khalil Al Farsi, Murtadha K. Al-Khabori, Salam Al-Kindi, Yasser Wali
Journal: Blood (2015)
Randomized, single-blind, crossover trial comparing the antiemetic effect of tropisetron or generic ondasetron plus corticosteriods in patients receiving high dose cisplatin-containing chemotherapy
Authors: S. Subongkot, Y. Payanta, A. Sookprasert
Journal: Journal of Clinical Oncology (2008)

20700 Background/Purpose: To compare the antiemetic efficacy and tolerability of tropisetron plus corticosteriods with generic form of ondansetron plus corticosteriods during multiple-day of high dose cisplatin-based chemotherapy. Methods: 41 cancer patients with recurrent head and neck cancer, head and neck cancer, soft tissue sarcoma, non small cell lung cancer or osteogenic sarcoma scheduled to receive at least 2 cycles of high dose cisplatin-based chemotherapy (≥50 mg/m2/day up to 5 days) given every 3 weeks were included. A single-blind crossover trial design was used and patients randomized to tropisetron plus dexamethasone or generic ondasetron plus dexamethasone. In an experimental arm, tropisetron was administered as a single 5 mg intravenous dose with dexamethasone 10 mg orally on days 1–5 while a single 24 mg intravenous dose with dexamethasone 10 mg orally on day 1–5 were given in the control arm. The treatments were crossed over as cancer patients receiving subsequent cycles of chemotherapy. Results: 41 patients were evaluable for efficacy during March 2006 to November 2006. Similar advantages were obtained with the two treatments. Side effects were generally few and mild with both treatments and no significant differences were found. Conclusions: This is the first trail in Thailand conducted at Srinagarind hospital, Khon Kaen University, Thailand to demonstrate the efficacy of tropisetron against generic form of ondasetron. Tropisetron and generic ondasetron plus corticosteriods provided a comparable antiemetic efficacy in cancer patients receiving high dose cisplatin-based chemotherapy. As newer antiemetics such as the neurokinin (1) receptor antagonist already existed, a future trial should evaluate effect of this drug in optimizing antiemetic therapy in patients receiving high dose cisplatin containing regimens. Time After Chemotherapy (h) Drug No. (%) of Patients by Efficacy Class Completely Effective Moderate Effective Slightly Effective Not Effective p 0-6 Tropisetron 38 (92.7) 2 (4.9) 1 (2.4) 0 (0) 0.102 Ondansetron 34 (82.9) 6 (14.6) 1 (2.4) 0 (0) 6-12 Tropisetron 37 (90.2) 3 (7.3) 1 (2.4) 0 (0) 0.317 Ondansetron 39 (95.1) 2 (4.9) 0 (0) 0 (0) 12-18 Tropisetron 38 (92.7) 3 (7.3) 0 (0) 0 (0) 0.480 Ondansetron 37 (90.2) 3 (7.3) 1 (2.4) 0 (0) 18-24 Tropisetron 29 (70.7) 10 (24.4) 2 (4.9) 0 (0) 0.371 Ondansetron 26 (63.4) 12 (29.3) 3 (7.3) 0 (0) No significant financial relationships to disclose.
Influence of Information Framing on Patient Decisions to Treat Actinic Keratosis
Authors: Katherine Berry, Melissa Butt, Joslyn S. Kirby
Journal: JAMA Dermatology (2017)

<h3>Importance</h3> Actinic keratosis (AK) is a skin growth induced by UV light exposure that requires long-term management because a small proportion of the disease can progress to squamous cell carcinoma. The influence of how clinicians frame or present information to patients may affect decision making about AK. <h3>Objective</h3> To evaluate the differences in patients' decisions on whether to receive treatment for AK related to information presentation or choice framing. <h3>Design, Setting, and Participants</h3> A prospective survey study was performed from June 1 to July 31, 2016, in participants who were able to read English. Participants were recruited through the Penn State Milton S. Hershey Dermatology Clinic and an online survey site. The survey was conducted through an online portal. A total of 571 individuals were recruited. Regression analysis, correlation coefficient analysis, and test-retest validation were conducted. <h3>Main Outcomes and Measures</h3> The proportions of patients choosing to receive treatment for AK. Analyses were performed to adjust for age, sex, educational level, history of skin cancer, and history of AK. <h3>Results</h3> Of the 571 recruited participants, 539 (94.4%) returned completed surveys. The mean (SD) age of respondents was 42.9 (17.8) years; 306 (56.8%) were women. The decision to receive treatment for AK varied from 57.7% (n = 311) to 92.2% (n = 497) for the 5 scenarios presented in the questions (<i>P</i> &lt; .001). The question that presented AK as a "precancer" had the highest proportion of participants who preferred treatment (497 [92.2%]). Two questions that presented the risk of AK as not progressing to cancer had the lowest proportion of individuals who chose treatment (311 [57.7%] and 328 [60.9%]). Participants from the clinic and from the online portal were significantly different in age (mean [SD] age, 56.1 [17.6] vs 33.3 [10.0] years), sex (145 [63.6%] vs 161 [51.8%] were females), educational level (40 [17.5%] vs 80 [25.7%] had completed some graduate school), history of AK (46 [20.2%] vs 19 [6.1%] answered yes), and history of skin cancer (76 [33.3%] vs 15 [4.8%] answered yes) (all<i>P</i> ≤ .001). Based on a regression analysis, age, sex, and previous diagnosis of skin cancer were not significantly associated with the participants' responses. <h3>Conclusions and Relevance</h3> This study found that patients' decisions on whether to receive treatment for AK is significantly affected by physician wording, especially with alterations in the presentation of risk of malignant transformation.
Months Report from the Phase 3 Study of Plerixafor+G-CSF VS. Placebo+G-CSF for Mobilization of Hematopoietic Stem Cell for Autologous Transplant in Patients with NHL.
Authors: John F. DiPersio, Ivana NM Micallef, Patrick J. Stiff, Brian J. Bolwell, Richard Thomas Maziarz, Gary Bridger, Gary Calandra
Journal: Blood (2008)
Gene Expression and Ex Vivo Drug Sensitivity Profiles in Children with Acute Leukemia: An Insight for High-Dose Therapy and Role of Etoposide and Fludarabine.
Authors: Joanna Szczepanek, Michal Jarzab, Malgorzata Oczko-Wojciechowska, Malgorzata Kowalska, Andrzej Tretyn, Olga Haus, Monika Pogorzala, Mariusz Wysocki, Barbara Jarzab, Jan Styczynski
Journal: Blood (2009)
Correlation of <i>EGFR</i> and <i>KRAS</i> mutation status, response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and survival with histologic subtypes of adenocarcinoma of the lung
Authors: S. Hussain, M. F. Zakowski, M. G. Kris, M. Ladanyi, W. Pao, G. Riely, N. Rizvi, J. E. Gomez, V. Miller
Journal: Journal of Clinical Oncology (2005)

7080 Background: We described a classification for adenocarcinoma with a bronchioloalveolar component (Ebright M Ann Thorag Surg 2002; 74:1640)dividing tumors into 3 categories: pure BAC, BAC with invasion, and adenocarcinoma with BAC features. In a series of 100 surgically treated patients characterized in this manner, outcome varied by stage aand clinical pattern but not by histology. Additional studies have shown a correlation of BAC subtype with response to TKIs, the greatest response seen in patients classified as adenocarcinoma with BAC features. Recently a stronger association with response to TKI has been shown for mutations in EGFR. In this study, we analyzed a series of 63 NSCLC patients for EGFR and KRAS mutations, response to TKI, and survival and correlated these findings with histology as above. Methods: NSCLC were classified as pure BAC, adenocarcinoma with BAC features, adenocarcinoma, and poorly differentiated NSCLC. EGFR exons 18–24 and KRAS were sequenced. Response to TKIs was determined using standard criteria. Median survival was calculated by log-rank test. Results: Median survival differed significantly between patients with tumors showing a BAC component versus those that did not (p=0.02). BAC component did not correlate with EGFR mutation (p=0.19) or KRAS mutation status (p=0.27). There was a trend for BAC presence to be associated with response to TKIs (p=0.09). Conclusions: The presence of a BAC component is a predictor of survival and may be useful in drug selection for patients whose EGFR mutational status is unknown or cannot be ascertained. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Genentech AstraZeneca
Reply to L. Casadaban et al
Authors: Donna Niedzwiecki, Wendy L. Frankel, Alan P. Venook, Xing Ye, Paula N. Friedman, Richard M. Goldberg, Robert J. Mayer, Thomas A. Colacchio, Jude Marie Mulligan, Timothy S. Davison, Eamonn O'Brien, Peter Kerr, Patrick G. Johnston, Richard D. Kennedy, D. Paul Harkin, Richard L. Schilsky, Monica M. Bertagnolli, Robert S. Warren, Federico Innocenti
Journal: Journal of Clinical Oncology (2017)
Monoclonal and Oligoclonal Bands After Single Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: Impact On Overall Survival and Progression-Free Survival
Authors: Victor Hugo Jimenez-Zepeda, Norman Franke, Andrew Winter, Suzanne Trudel, Christine I. Chen, Rodger E. Tiedemann, Vishal Kukreti
Journal: Blood (2012)
Radiotracer Injection Into the Catheter Balloon
Authors: Toktam Massoudi, Hamed Shayegani, Ramin Sadeghi
Journal: Clinical Nuclear Medicine (2017)

We reported a 4-year-old girl with history of bilateral vesicoureteral reflux who underwent direct radionuclide cystography in our department. Radiotracer was mistakenly injected in the catheter balloon. The filling phase showed no change in the bladder volume, and the catheter balloon was apparent as an intense activity in the base of the bladder. The procedure was repeated with correct injection of the tracer into the catheter. Wrong injection of the radiotracer into the catheter balloon should always be borne in mind in similar cases.
Association of <i>GSTP1</i>, <i>COMT</i>, and <i>TPMT</i> with testicular cancer (TC) treatment outcome after cisplatin-based chemotherapy (CBCT).
Authors: Chunkit Fung, David J. Vaughn, Nandita Mitra, Stephanie L. Ciosek, Saran Vardhanabhuti, Katherine L. Nathanson, Peter A. Kanetsky
Journal: Journal of Clinical Oncology (2012)

344 Background: Genetic variation in GSTP1, COMT, and TPMT, which are genes important to the metabolism of cisplatin, may affect TC treatment outcome. We hypothesized that single nucleotide polymorphisms (SNPs) of these genes causing increased cisplatin metabolism may be associated with worse treatment outcome. Methods: TC patients who had CBCT, ≥ 1 year of follow-up since initiation of CBCT, and genotyping completed as part of a genome-wide association study were included. After excluding markers with genotyping call rates of &lt; 90%, we analyzed 3, 43, and 44 SNPs each for GSTP1, COMT, and TPMT respectively. We evaluated three endpoints: refractory disease (RD) as defined by radiographic or serologic evidence of TC after initial CBCT; progression-free survival (PFS); and overall survival (OS). We studied SNP association with these endpoints assuming additive, recessive, and dominant genetic models and adjusted p-values for false discovery rate to account for multiple comparisons. Results: 137 patients (82.5% white, median age of 31 years) were recruited. Among them, 81.7% had non-seminoma and 68.6%, 8.0% and 22.6% were in good, intermediate, and poor IGCCC prognostic group respectively. 33.6%, 62.0%, 0.7%, and 2.9% had EP, BEP, TIP, and VIP respectively as initial CBCT with a mean total cisplatin dose of 345.3 mg/m 2 . After initial CBCT, 8.0% developed RD; among the remaining 92.0%, 23.8% had recurrent TC after a mean follow-up of 46.8 months. We found no statistically significant associations of our SNPs with PFS or OS. However, the COMT rs2073743 G allele conferred a higher risk of RF. It was present in 40.9% of patients with RD versus 21.1% of those without. Assuming recessive inheritance, patients with rs2073743 GG had over 20-fold increased odds (odds ratio = 22.69, (95% CI 3.3 – 155.8) ) of RD compared to those who carry at least one C allele. After adjusting for race, IGCCC, primary site of disease, type of CBCT, and total cisplatin dose, this association was no longer statistically significant. Conclusions: COMT rs2073743 may be associated with RD, but replication and validation studies will be imperative to confirm this finding.
Does High Dose Cytosine Arabinoside Improves Disease Free Survival for Down Syndrome Acute Myelocytic Leukemia Patients?.
Authors: Mahasen Saleh, Ashraf Khairy, Mohammed Al-Mahr, Hassan El-Solh, AbdulRahman Al-Musa, Ibrahim El-Hassan, Asim F. Belgaumi
Journal: Blood (2005)